首页> 外文期刊>JAMA: the Journal of the American Medical Association >Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae (see comments)
【24h】

Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae (see comments)

机译:β-内酰胺的低剂量和长治疗持续时间:携带耐青霉素的肺炎链球菌的危险因素(参见评论)

获取原文
获取原文并翻译 | 示例
       

摘要

CONTEXT: The spread of drug-resistant Streptococcus pneumoniae in the community is a public health problem in developed and developing nations, but whether antibiotic use is responsible for the increase in drug resistance is not known. OBJECTIVE: To analyze the relationship between penicillin-resistant S pneumoniae (PRSp) pharyngeal carriage and characteristics of beta-lactam use. DESIGN: Observational study of children attending 20 randomly sampled schools. SETTING: The Loiret, in the center of France. PARTICIPANTS: A total of 941 children, 3 to 6 years old. MAIN OUTCOME MEASURE(S): Pharyngeal carriage of S pneumoniae, antibiotic use, and medical events during the preceding 30 days. Pneumococcal penicillin G sodium minimal inhibitory concentrations and serotyping were performed. RESULTS: Medical illnesses and the use of antibiotics were not associated with PRSp carriage. However, oral beta-lactam use was associated with an increased risk of PRSp carriage (odds ratio [OR], 3.0; 95% confidence interval [CI], 1.1-8.3; P=.03). Children treated by low daily doses of an oral beta-lactam (defined as lower than clinical recommendations) had an increased risk of PRSp carriage, as compared with children who did not (OR, 5.9; 95% CI, 2.1-16.7; P=.002). A treatment of long duration (>5 days) with a beta-lactam was associated with an increased risk of PRSp carriage (OR, 3.5; 95% CI, 1.3-9.8; P=.02). CONCLUSIONS: Our results suggest that a low daily dose and a long duration of treatment with an oral beta-lactam contribute to the selective pressure in promoting pharyngeal carriage of PRSp.
机译:背景:耐药性肺炎链球菌在社区中的传播是发达国家和发展中国家的公共卫生问题,但未知抗生素的使用是否导致耐药性增加。目的:分析耐青霉素性肺炎链球菌(PRSp)咽部运输与β-内酰胺使用特征之间的关系。设计:对在20所随机抽样学校就读的儿童的观察性研究。地点:卢瓦尔河,在法国中部。参加者:共有941名3至6岁的儿童。主要观察指标:在过去30天内,咽部携带肺炎链球菌,使用抗生素和发生医疗事件。进行了肺炎球菌青霉素G钠最低抑菌浓度和血清分型。结果:医疗疾病和抗生素的使用与PRSp的运输无关。但是,口服β-内酰胺会增加PRSp携带风险(几率[OR]为3.0; 95%置信区间[CI]为1.1-8.3; P = .03)。与未接受口服低剂量口服β-内酰胺治疗的儿童(未定义为低于临床建议)相比,PRSp携带的风险增加(OR,5.9; 95%CI,2.1-16.7; P = .002)。用β-内酰胺长时间(> 5天)治疗会增加PRSp转运的风险(OR,3.5; 95%CI,1.3-9.8; P = .02)。结论:我们的研究结果表明,口服β-内酰胺的低日剂量和长疗程有助于促进PRSp咽部运输的选择性压力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号